Organon : Q1 2024 Transcript - MarketScreener
Corrected Transcript 02-May-2024 Organon & Co. Q1 2024 Earnings Call ...
Source: marketscreener.com
Lilly Emgality News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lilly Emgality. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lilly Emgality Today - Breaking & Trending Today
Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript February 15, 2024 Organon & Co. beats earnings expectations. Reported EPS is $0.88, expectations were $0.8. Organon & Co. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]
Source: yahoo.com
Eli Lilly's migraine drug fails to meet main goal in post-approval study
Eli Lilly said on Friday its drug Emgality did not meet the primary goal of superiority to Pfizer Inc's Nurtec ODT in prevention of episodic migraine in a post-approval study. This was... | June 16, 2023
Source: marketscreener.com
Eli Lilly Ordered to Pay $176.5 Million to Teva in US Migraine Drug Patent Trial
Eli Lilly must pay Teva Pharmaceuticals International $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.
Source: medscape.com
Eli Lilly ordered to pay $176.5 mln to Teva in US migraine drug patent
Eli Lilly Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine wheth
Source: jpost.com